M6ATCELL Exploiting fundamental insights of m6A methylation on CD8 T cell differentiation and function to boost medicinal T cell products
- Coordinator
- Stichting Sanquin Bloedvoorziening, Netherlands
- Runs
- 1 April 2023 to 30 September 2025
- Status
- Ended early
- EU funding
- €235k
- Total cost
- —
- Partners
- 2 organisations in 1 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101107176
What the project is doing
In the project's own words, from its summary on CORDIS.
Adoptive T cell therapies have revolutionised cancer treatment in some haematological tumours. Despite astounding advances, patients often relapse because the transferred T cells have low persistence and they lose their effector function against cancer cells. The prime challenge for improving T cell therapies is to decipher the mechanisms that define T cell effector function and memory formation. The MA6TCELL project aims to disentangle this problem by defining how m6A methylation on mRNA regulates human CD8 T cell differentiation and function. m6A is the most abundant mRNA methylation and determines gene expression by regulating mRNA metabolism, altering as such cell function.
Using the miCLIP assay, I previously mapped genome-wide the m6A sites on the mRNAs of human CD8 T cells (unpublished data I will provide the host with). This map revealed that m6A occurs not only at the known DRACH sequences, but also at AU-rich sequences (AREs). Intriguingly, the host has uncovered that AREs are critical regulators of cytokine production in memory CD8 T cells (host expertise). My pilot experiments revealed that chemical inhibition of a m6A demethylase in CD8 T cells decreased cytokine production, further supporting my hypothesis that m6A methylation controls CD8 T cell differentiation and function.
To test this hypothesis the M6ATCELL project will: 1) define the regulatory mechanisms of m6A methylation in human CD8 T cell differentiation and effector function and 2) test whether m6A enzyme inhibitors improve the potency of CD8 T cell therapies using chimeric antigen receptor (CAR) T cells. Our findings will yield fundamental insights in T cell biology, which can be relevant for multiple adoptive T cell therapies.
My long-term aim is to transfer my scientific findings from bench-to-bedside. Thus, I also secured a placement at the European Medicines Agency and if this proposal is granted, I will be trained on the regulatory guidelines of medicinal T cell products.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Sanquin Bloedvoorziening | Amsterdam | Netherlands | Coordinator |
| The European Medicines Agency | Amsterdam | Netherlands | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI